Deletion of 11q22 (ATM) and 17p13.1 (TP53) are recurring abnormalities of Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic lymphoma (SLL). According to current NCCN CLL guidelines, deletions of 11q22 and 17p13.1 are classified as an unfavorable cytogenetic risk factor.
This test can be ordered individually or as part of a CLL Full Panel, CLL Prognostic Panel, or CLL Progressive Panel. See the individual panel tests for more details.
Bone marrow aspirate:
Collect bone marrow aspirate in a sterile Sodium heparin (Na hep) syringe and transfer to a sterile vial/tube
- or -
Transfer aspirate from syringe to transport container.
Submit entire specimen unspun.
Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting.
Submit entire specimen unspun
AHL Cytogenetics Oncology Request
Fluorescence in situ hybridization (FISH)
Normal or Abnormal with interpretation.